Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Voltage-dependent anion-selective channel protein 1 (VDAC1) is a β-barrel ion channel located in the outer mitochondrial membrane, ubiquitously expressed across eukaryotic cells[1][2][3][4][6]. It is the primary gateway for the movement of small hydrophilic molecules, nucleotides, and ions (such as ATP, ADP, Ca^2+^) between the mitochondria and cytosol, directly linking mitochondrial energetics to cytoplasmic metabolic demand[1][2][4]. VDAC1’s conformational state is voltage-dependent, alternating between open (anion-selective, high conductance) and closed (cation-selective, low conductance) forms[1][2][3][5]. Functionally, VDAC1 interacts with metabolic enzymes (such as hexokinase) and apoptosis-regulating proteins (such as Bcl-2 family members), acting as a central regulator of cell life and death, including the release of apoptotic factors like cytochrome c[4][6]. Dysregulation of VDAC1 is implicated in many diseases, including cancer (where it is often overexpressed), neurodegenerative disorders, diabetes, and cardiovascular disease[2][4][6]. As such, VDAC1 is considered a highly promising therapeutic target with ongoing drug development focused on modulating its function for cancer and other disorders[6].
Blocking or modulating VDAC1 affects mitochondrial permeability and apoptosis. Disruption of interaction with Bcl-2 family proteins or hexokinase promotes apoptosis in cancer cells. Modulation of Ca^2+^ and ATP flux through outer mitochondrial membrane.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Voltage-dependent anion-selective channel protein 1 (VDAC1).